Precigen, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PGEN Nasdaq 2836 precigen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Precigen, Inc.

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - Jan 12th, 2026 6:00 am
High Growth Tech Stocks In The US For January 2026 - Jan 9th, 2026 4:38 am
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 2:05 pm
Exploring US High Growth Tech Stocks for Potential Expansion - Dec 24th, 2025 4:38 am
US High Growth Tech Stocks To Watch December 2025 - Dec 17th, 2025 4:38 am
Spotlighting Bridgewater Bancshares And 2 Other Growth Stocks With Strong Insider Ownership - Dec 16th, 2025 4:35 am
Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company - Dec 14th, 2025 5:21 am
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet? - Dec 2nd, 2025 2:38 pm
High Growth Tech Stocks in the US for November 2025 - Nov 24th, 2025 10:38 am
US High Growth Tech Stocks to Watch in November 2025 - Nov 17th, 2025 4:38 am
Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... - Nov 13th, 2025 10:01 pm
Precigen Reports Third Quarter 2025 Financial Results and Business Updates - Nov 13th, 2025 2:05 pm
November 2025's Leading Growth Companies With High Insider Ownership - Nov 11th, 2025 4:35 am
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 - Nov 6th, 2025 2:30 pm
Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS - Oct 26th, 2025 4:05 am
A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis - Oct 16th, 2025 10:25 pm
3 High Growth Stocks With Strong Insider Ownership - Oct 13th, 2025 11:35 am
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - Oct 13th, 2025 5:00 am
Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization - Sep 23rd, 2025 5:23 pm
Precigen, Inc. (NASDAQ:PGEN): Is Breakeven Near? - Sep 23rd, 2025 4:41 am